Daré Bioscience (DARE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Voting matters and shareholder proposals
Annual Meeting of Stockholders scheduled for June 11, 2026, with voting available online, by phone, or through brokers and banks.
Shareholders must provide voting instructions to brokers or banks to ensure their shares are voted on all matters.
Voting deadlines for shares held through intermediaries may be earlier than the meeting date.
Proxy materials, including the Notice, Proxy Statement, and Form 10-K, are accessible online.
The meeting will be held virtually, allowing remote participation and voting.
Shareholder rights and capital structure
Emphasis on the importance of every shareholder vote and participation in the annual meeting.
Instructions provided for both direct and beneficial shareholders to ensure all shares are represented.
Latest events from Daré Bioscience
- Revenue rose and losses narrowed, but going concern and Nasdaq delisting risks remain.DARE
Q2 2026 - Commercial launches and clinical milestones mark a pivotal growth phase, backed by strong funding.DARE
Virtual Investor Closing Bell - Imminent launches and clinical milestones position the pipeline for strong near-term growth.DARE
TD Cowen 46th Annual Health Care Conference - All eight proposals, including director elections and stock plan amendments, were approved.DARE
AGM 2026 - Okapi Partners LLC engaged for proxy solicitation ahead of the 2026 annual meeting.DARE
Proxy filing - First product revenue expected June 2026, but ongoing viability depends on new capital.DARE
Q1 2026 - Annual meeting covers director elections, compensation, auditor, and share issuance proposals.DARE
Proxy filing - Shareholders will vote on director elections, auditor ratification, compensation, and key capital proposals.DARE
Proxy filing - Proxy covers director elections, auditor ratification, compensation, and key capital structure proposals.DARE
Proxy filing